Indivior Pharmaceuticals (INDV) Net Cash Flow (2024 - 2026)

Indivior Pharmaceuticals' Net Cash Flow history runs 3 years deep, the most recent figure standing at -$21.0 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 139.62% year-over-year to -$21.0 million; the TTM figure through Mar 2026 stood at -$197.0 million (down 258.87% YoY), while the FY2025 annual figure was -$123.0 million, down 4200.0% from the prior year.
• Net Cash Flow was -$21.0 million for Q1 2026 at Indivior Pharmaceuticals, up from -$250.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $136.0 million in Q2 2025 to a low of -$250.0 million in Q4 2025.
• Historically, Net Cash Flow has averaged -$15.7 million across 3 years, with a median of -$14.0 million in 2024.
• Biggest YoY gain for Net Cash Flow was 177.94% in 2025; the steepest drop was 906.45% in 2025.
• A 3-year view of Net Cash Flow shows it stood at $31.0 million in 2024, then slumped by 906.45% to -$250.0 million in 2025, then surged by 91.6% to -$21.0 million in 2026.
• The last three Net Cash Flow figures came in at -$21.0 million (Q1 2026), -$250.0 million (Q4 2025), and -$62.0 million (Q3 2025), per Business Quant data.